Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026)

Lantheus Holdings' (LNTH) quarterly Total Non-Current Liabilities came in at $1.1 billion in Q1 2026, up 24.32% year-on-year from $872.3 million in Q1 2025, and up 5.31% on a QoQ basis from $1.0 billion in Q4 2025.

Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has 13 years of Total Non-Current Liabilities data on file, last reported at $1.1 billion in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 24.32% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 24.32% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 16.71% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $1.1 billion, up from $1.0 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for LNTH reached as high as $1.2 billion in Q3 2025 and fell as low as $395.8 million in Q1 2022.
  • Historically, Total Non-Current Liabilities has averaged $813.2 million across 5 years, with a median of $851.6 million in 2022.
  • Across the five-year window, Total Non-Current Liabilities soared 124.98% in 2022 and slipped 6.63% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $851.6 million in 2022, then slipped by 4.61% to $812.3 million in 2023, then gained by 8.62% to $882.3 million in 2024, then gained by 16.71% to $1.0 billion in 2025, then increased by 5.31% to $1.1 billion in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.1 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Lantheus Holdings 6.72 Bn 6.22 Bn 230.92 Mn 1.08 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.08 Bn
Dec 31, 2025 1.03 Bn
Sep 30, 2025 1.16 Bn
Jun 30, 2025 949.16 Mn
Mar 31, 2025 872.29 Mn
Dec 31, 2024 882.33 Mn
Sep 30, 2024 846.69 Mn
Jun 30, 2024 888.05 Mn
Mar 31, 2024 822.69 Mn
Dec 31, 2023 812.34 Mn
Sep 30, 2023 760.00 Mn
Jun 30, 2023 782.08 Mn
Mar 31, 2023 881.13 Mn
Dec 31, 2022 851.57 Mn
Sep 30, 2022 411.40 Mn
Jun 30, 2022 396.88 Mn
Mar 31, 2022 395.80 Mn
Dec 31, 2021 378.51 Mn
Sep 30, 2021 258.83 Mn
Jun 30, 2021 257.87 Mn